Public-domain · open source
OpenJurist
← 405 F.3d 515 - United States v. Turcotte

United States v. Turcotte’s Empirical Analysis

405 F.3d 515 · 2005

Citation profile

97
cited by 97 later decisions
2
cited 2 times by the Supreme Court
7
states following
July 2024
most recently cited

37 federal appellate · 4 district · 10 state decisions

How this case has been cited

Cited by 97 later decisions (2 by the Supreme Court) — most recently July 2024 · most notably United States v. Brown (2005), 135 S. Ct. 2298 - McFadden v. United States (2015)

37 federal appellate · 4 district · 10 state decisions

500200520102020decided

Later decisions citing this case, by decade. The current decade is in progress, and our corpus holds fewer opinions from the most recent years, so the latest bars are undercounted — not a real decline.

Relationships

Relies on Strickland v. Washington · Brady v. State of Maryland · Hoffman Estates v. Flipside, Hoffman Estates, Inc. · Sandstrom v. Montana · Kolender v. Lawson

Most-quoted passages

The sentences later courts lift from this opinion, ranked by how many decisions quote each — the parts of the opinion doing the work. These counts are smaller than the citation total above because most of the 97 citing decisions cite the case generally; a passage count includes only decisions quoting that exact language verbatim.

  1. “(i) the chemical structure of which is substantially similar to the chemical structure of a controlled substance in schedule I or II; (ii) which has a stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance in schedule I or II; or (iii) with respect to a particular person, which such person represents or intends to have a stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance in schedule I or II.”
    3 later decisions quote this exact passage · from the majority
  2. “In this circuit, unsupported and undeveloped arguments are waived.”
    3 later decisions quote this exact passage · from the majority
  3. “[T]he term "controlled substance analogue" in § 813 is clearly and specifically defined, in terms readily comprehensible to the ordinary reader. It provides adequate notice of what conduct is prohibited. The statute makes plain that drugs which have been chemically designed to be similar to controlled substances, but which are not themselves listed on the controlled substance schedules, will nonetheless be considered as schedule I substances if 1) they are substantially similar chemically to drugs that are on those schedules, 2) if they produce similar effects on the central nervous system as drugs that are on those schedules, or 3) are intended or represented to produce effects similar to those produced by drugs that are on those schedules. There is nothing vague about the statute.”
    2 later decisions quote this exact passage · from the majority

How this case has been treated — in progress

Whether each later court followed, distinguished, criticized, or overruled this decision. The treatment classification (task #35) runs highest-cited cases first and lights up here as it reaches this one.